- Home
- ESPR
as 12-24-2024 4:00pm EST
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 399.0M | IPO Year: | 2013 |
| Target Price: | $7.30 | AVG Volume (30 days): | 8.8M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.58 - $3.94 | Next Earning Date: | 11-07-2024 |
| Revenue: | $295,451,000 | Revenue Growth: | 187.12% |
| Revenue Growth (this year): | 186.9% | Revenue Growth (next year): | 31.10% |
Stock Insider Trading Activity of Esperion Therapeutics Inc. (ESPR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Warren Eric | ESPR | Chief Commercial Officer | Dec 17 '24 | Sell | $2.43 | 2,234 | $5,426.39 | 160,121 | |
| Koenig Sheldon L. | ESPR | President and CEO | Dec 17 '24 | Sell | $2.47 | 12,447 | $30,694.30 | 739,819 | |
| Warren Eric | ESPR | Chief Commercial Officer | Nov 19 '24 | Sell | $2.17 | 197 | $426.51 | 160,121 | |
| Warren Eric | ESPR | Chief Commercial Officer | Oct 17 '24 | Sell | $2.12 | 107 | $226.73 | 160,121 |
Latest Esperion Therapeutics Inc. News
ESPR Breaking Stock News: Dive into ESPR Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt
GlobeNewswire
8 days ago
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
MT Newswires
9 days ago
Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target
MT Newswires
13 days ago
Esperion Swaps New Notes, Cash for $210 Million of Convertible Debt; Shares Slump Pre-Bell
GlobeNewswire
13 days ago
Esperion Announces $210 Million Convertible Debt Financing
MT Newswires
14 days ago
Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel
GlobeNewswire
14 days ago
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Zacks
23 days ago
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Compare ESPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ESPR Esperion Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.